Evidence map›Paper›PMID 36927975›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Remission Induction of IgG4-related Membranous Nephropathy with Multitarget Therapy.

Yoshitaka Furuto, Hirotsugu Hashimoto, Akio Namikawa, Teppei Morikawa, Yuko Shibuya

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yoshitaka FurutoDepartment of Hypertension and Nephrology, NTT Medical Center Tokyo, Japan.
Hirotsugu HashimotoDepartment of Diagnostic Pathology, NTT Medical Center Tokyo, Japan.
Akio NamikawaDepartment of Hypertension and Nephrology, NTT Medical Center Tokyo, Japan.
Teppei MorikawaDepartment of Diagnostic Pathology, NTT Medical Center Tokyo, Japan.
Yuko ShibuyaDepartment of Hypertension and Nephrology, NTT Medical Center Tokyo, Japan.
NTT Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgG4-related membranous nephropathy (MN) is often refractory to glucocorticoid (GC) therapy, and treatment remains unclear. We herein report a 67-year-old Japanese man with IgG4-related MN and tubulointerstitial nephritis. A post-gastroscopy antibody test revealed Helicobacter pylori infection. After eradication, his proteinuria decreased indefinitely. We started prednisolone (30 mg/day), long-term GCs, and immunosuppressant therapy. However, remission proved challenging to achieve, with persistent proteinuria present at 1.0-2.0 g/gCr. We performed multitarget therapy for refractory IgG4-related MN, achieving proteinuria remission (<0.3 g/gCr). Multitarget therapy with low-dose GCs can resolve refractory IgG4-related MN through remission induction of proteinuria and minimize the risks associated with GC therapy.

Indexed as

Glomerulonephritis, MembranousHelicobacter InfectionsHelicobacter pyloriAgedHumansImmunoglobulin GMaleProteinuriaRemission InductionImmunoglobulin GHelicobacter pyloriIgG4 kidney diseasemembranous nephropathymultitarget therapytubulointerstitial nephritis

Identifiers

PMID36927975
PMCPMC10686725
OpenAlexW4324265662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.